       Document 0856
 DOCN  M95A0856
 TI    Inhibition of HIV-1 by a double transdominant fusion gene.
 DT    9510
 AU    Aguilar-Cordova E; Chinen J; Donehower LA; Harper JW; Rice AP; Butel JS;
       Belmont JW; Department of Pediatrics, Baylor College of Medicine,
       Houston, TX; 77030, USA.
 SO    Gene Ther. 1995 May;2(3):181-6. Unique Identifier : AIDSLINE
       MED/95339003
 AB    A double transdominant fusion gene (trev) designed to inhibit two
       essential HIV functions simultaneously was constructed by linking tat
       and rev transdominant mutants. Trev independently inhibited both Tat and
       Rev functions, localized within the nucleus and cells transfected with
       trev showed a stable inhibition of HIV-1-mediated cytopathicity. A
       retroviral vector of trev was made and shown also to confer protection
       from HIV cytopathic effects. Simultaneous inhibition of two essential
       viral genes presents significant advantages for potential gene therapy
       treatment of HIV infection over conventional single effect molecules.
 DE    Amino Acid Sequence  Base Sequence  Cells, Cultured  *Cloning, Molecular
       Cytopathogenic Effect, Viral  Gene Products, rev/PHYSIOLOGY  Gene
       Products, tat/PHYSIOLOGY  *Genes, rev  *Genes, tat  Genes,
       Dominant/GENETICS  Genetic Vectors/GENETICS  Human  HIV-1/*PHYSIOLOGY
       Luciferase/GENETICS  Molecular Sequence Data  Recombinant Fusion
       Proteins/BIOSYNTHESIS  Sequence Deletion  Support, Non-U.S. Gov't
       Support, U.S. Gov't, P.H.S.  Transfection  Virus Replication  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

